Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses
| Status: | Completed |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 3/27/2019 |
| Start Date: | September 4, 2014 |
| End Date: | June 8, 2015 |
The Sonatherm device provides both advanced imaging (ultrasound guidance) and high intensity
focused ultrasound to target and ablate tumors. It also does not require piercing the tumor
with a needle as does cryotherapy (Cryo) and radiofrequency (RF) ablation. Cryo and RF also
have high retreatment rates due the finding of untreated tumor on follow-up imaging. Thus,
there is reason to hypothesize that Sonatherm with it's real-time ultrasound imaging feedback
could replace RF and Cryo for the treatment of small renal masses where the invasiveness of
full resection partial nephrectomy is contraindicated due to patient comorbidities.
focused ultrasound to target and ablate tumors. It also does not require piercing the tumor
with a needle as does cryotherapy (Cryo) and radiofrequency (RF) ablation. Cryo and RF also
have high retreatment rates due the finding of untreated tumor on follow-up imaging. Thus,
there is reason to hypothesize that Sonatherm with it's real-time ultrasound imaging feedback
could replace RF and Cryo for the treatment of small renal masses where the invasiveness of
full resection partial nephrectomy is contraindicated due to patient comorbidities.
This study uses a treat and resect model where ablation is followed by a partial nephrectomy.
This will allow for the ablation to be evaluated for necrosis and targeting accuracy. It will
also ensure cancer safety prior validation of the HIFU device. The applied heat of HIFU
ablation could improve hemostasis and blood loss.
This will allow for the ablation to be evaluated for necrosis and targeting accuracy. It will
also ensure cancer safety prior validation of the HIFU device. The applied heat of HIFU
ablation could improve hemostasis and blood loss.
Inclusion Criteria:
1. ≥ 18 years of age.
2. Must provide written informed consent
3. Must have presence of an enhancing solid renal mass ≤ 3.0 cm on CT or MRI
4. Must be scheduled for laparoscopic robot assisted partial nephrectomy of renal mass.
5. Must have an expected survival status of at least 3 months.
6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
7. Previous chemotherapy, and/or biological therapy for cancer are permitted. The subject
should have recovered from the effects of these or of any prior surgery.
8. Women of child bearing potential must have negative pregnancy test (urine or serum)
prior to study enrollment. Females must agree to adequate birth control if conception
is possible during the study.
9. All toxicities from prior therapy must be recovered to a grade 1 or better according
to the Clavien-Dindo Classification system.
10. If previous biopsy of mass has been done, pathology must be consistent with renal cell
carcinoma (RCC).
Exclusion Criteria
1. < 90% solid component of the tumor on screening cross-sectional imaging (CT/MRI)
2. Prior ablative or surgical treatment of the lesion
3. Masses located close to the hilar vessels or at locations that cannot be accessed with
the HIFU probe
4. The patient has only one kidney
5. Multiple or bilateral renal masses
6. Failure to meet the following laboratory levels on preoperative screening:
1. Platelet count ≥ 100,000 mm3
2. Hemoglobin ≥ 10 g/dl.
3. Prothrombin Time (PT) ≤ 1.5 times upper limit of laboratory normal (ULN).
4. Activated partial thromboplastin time (aPTT) ≤ 1.5 times ULN.
5. Serum creatinine < 2.5 times ULN.
7. Hepatic toxicity grade 2 (using CTCAE version 4 standard definitions)
8. Inability to hold anticoagulation for surgery due to high risk of a cerebral vascular
event, myocardial event, or like risk (ASA may be continued)
9. Abdominal obesity that would, in the assessment of the PI, make the HIFU ablation
difficult
10. Participation in another investigational trial concurrently or within 30 days prior to
enrollment
11. Subjects with a diagnosis of metastatic disease who are currently receiving treatment
or who are not in remission
12. Significant acute or chronic medical, neurologic, or psychiatric illness in the
subject that, in the judgment of the Principal Investigator, could compromise subject
safety, limit the subject's ability to complete the study, and/or compromise the
objectives of the study
We found this trial at
1
site
Indianapolis, Indiana 46202
Principal Investigator: Chandru Sundaram, MD
Phone: 317-274-1798
Click here to add this to my saved trials
